{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:27:39Z","timestamp":1778614059986,"version":"3.51.4"},"reference-count":25,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Zoledronic acid (ZA) administered during the initial hospitalization for a fragility fracture improves the osteoporosis pharmacotherapy rate. Distinguishing the safety profile of inpatient ZA (IP-ZA) in this context is crucial if this approach is to be widely adopted.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To study the acute safety profile of IP-ZA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>An observational study of patients admitted to the Massachusetts General Hospital with fragility fractures who were eligible to receive IP-ZA. Patients were treated with or without IP-ZA. Acetaminophen, either as a single pre-ZA dose or standing multiple-doses-per-day regimen for 48 hours or longer after ZA infusion, was also administered along with protocolized vitamin D and calcium supplementation. Changes in body temperature, serum creatinine, and serum calcium were measured.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 285 consecutive patients, meeting inclusion and exclusion criteria, are included in this analysis; 204 patients received IP-ZA. IP-ZA treatment was associated with a transient mean rise of body temperature of 0.31 \u00b0C on the day following its administration. Temperatures above 38 \u00b0C were seen in 15% of patients in the IP-ZA group and 4% in the nontreated group. Standing multiple-doses-per-day but not a single pre-ZA dose of acetaminophen effectively prevented this temperature increase. IP-ZA did not affect serum creatinine levels. Mean levels of serum total calcium and albumin-corrected calcium decreased by 0.54 mg\/dL and 0.40 mg\/dL, respectively, at their nadirs (Day 5). No patient experienced symptomatic hypocalcemia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>IP-ZA along with standing multiple-doses-per-day acetaminophen, administered to patients in the immediate postfracture period, is not associated with significant acute adverse effects.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgad295","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T11:12:59Z","timestamp":1685013179000},"page":"e1282-e1288","source":"Crossref","is-referenced-by-count":10,"title":["Safety of Inpatient Zoledronic Acid in the Immediate Postfracture Setting"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5081-4809","authenticated-orcid":false,"given":"WuQiang","family":"Fan","sequence":"first","affiliation":[{"name":"Endocrine Unit, Massachusetts General Hospital , Boston, MA 02114 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin Z","family":"Leder","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Massachusetts General Hospital , Boston, MA 02114 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0867-9778","authenticated-orcid":false,"given":"Michael","family":"Mannstadt","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Massachusetts General Hospital , Boston, MA 02114 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thuan V","family":"Ly","sequence":"additional","affiliation":[{"name":"Harvard Orthopaedic Trauma Initiative, Massachusetts General Hospital , Boston, MA 02114 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteban","family":"Franco-Garcia","sequence":"additional","affiliation":[{"name":"Division of Geriatrics, Massachusetts General Hospital , Boston, MA 02114 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcy B","family":"Bolster","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Massachusetts General Hospital , Boston, MA 02114 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"issue":"10","key":"2023101816055417300_dgad295-B1","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician's guide to prevention and treatment of osteoporosis","volume":"33","author":"LeBoff","year":"2022","journal-title":"Osteoporos Int"},{"issue":"1","key":"2023101816055417300_dgad295-B2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S2213-8587(22)00322-9","article-title":"Osteoporosis in the USA: prevention and unmet needs","volume":"11","author":"Khosla","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"2023101816055417300_dgad295-B3","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/jbmr.4747","article-title":"Additional insights on the osteoporosis care gap","volume":"38","author":"Talevski","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2023101816055417300_dgad295-B4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/ard.2008.092775","article-title":"Clinical subsequent fractures cluster in time after first fractures","volume":"68","author":"van Geel","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2023101816055417300_dgad295-B5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00198-018-4732-1","article-title":"Risk of subsequent fracture after prior fracture among older women","volume":"30","author":"Balasubramanian","year":"2019","journal-title":"Osteoporos Int"},{"issue":"9","key":"2023101816055417300_dgad295-B6","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1210\/jc.2017-02656","article-title":"Persistence of excess mortality following individual nonhip fractures: a relative survival analysis","volume":"103","author":"Tran","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023101816055417300_dgad295-B7","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/gerona\/glt105","article-title":"Death, debility, and destitution following hip fracture","volume":"69","author":"Tajeu","year":"2014","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"5","key":"2023101816055417300_dgad295-B8","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023101816055417300_dgad295-B9","first-page":"1389","article-title":"Leadership in orthopaedics: taking a stand to own the bone. American Orthopaedic Association position paper","volume":"87","author":"American Orthopaedic Association","year":"2005","journal-title":"J Bone Joint Surg Am"},{"issue":"9","key":"2023101816055417300_dgad295-B10","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1002\/jbmr.2301","article-title":"The osteoporosis treatment gap","volume":"29","author":"Kanis","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2023101816055417300_dgad295-B11","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1002\/jbmr.2202","article-title":"Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011","volume":"29","author":"Solomon","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"24","key":"2023101816055417300_dgad295-B12","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.2106\/JBJS.22.00469","article-title":"Secondary fracture rate after vertebral osteoporotic compression fracture is decreased by anti-osteoporotic medication but not increased by cement augmentation","volume":"104","author":"Mills","year":"2022","journal-title":"J Bone Joint Surg Am"},{"issue":"7","key":"2023101816055417300_dgad295-B13","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.2106\/JBJS.L.01781","article-title":"Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009","volume":"96","author":"Balasubramanian","year":"2014","journal-title":"J Bone Joint Surg Am"},{"issue":"19","key":"2023101816055417300_dgad295-B14","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2106\/JBJS.O.00768","article-title":"Osteoporosis and fragility fractures: what progress have we made?","volume":"97","author":"Jeray","year":"2015","journal-title":"J Bone Joint Surg Am"},{"issue":"1","key":"2023101816055417300_dgad295-B15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1210\/clinem\/dgac508","article-title":"Inpatient zoledronic acid and integrated orthopedic and fracture liaison services improve osteoporosis treatment rates","volume":"108","author":"Fan","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023101816055417300_dgad295-B16","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jamda.2018.02.005","article-title":"Can bisphosphonates prevent recurrent fragility fractures? A systematic review and meta-analysis of randomized controlled trials","volume":"19","author":"Lee","year":"2018","journal-title":"J Am Med Dir Assoc"},{"issue":"18","key":"2023101816055417300_dgad295-B17","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"issue":"18","key":"2023101816055417300_dgad295-B18","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"2023101816055417300_dgad295-B19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.4453","article-title":"Bone mineral density and bone turnover 10 years after a single 5 mg dose or two 5-yearly lower doses of zoledronate in osteopenic older women: an open-label extension of a randomized controlled trial","volume":"37","author":"Grey","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2023101816055417300_dgad295-B20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1210\/jc.2012-2868","article-title":"Reduction in the risk of clinical fractures after a single dose of zoledronic acid 5 milligrams","volume":"98","author":"Reid","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"25","key":"2023101816055417300_dgad295-B21","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","article-title":"Fracture prevention with zoledronate in older women with osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2023101816055417300_dgad295-B22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/jbmr.3877","article-title":"Secondary fracture prevention: consensus clinical recommendations from a multistakeholder coalition","volume":"35","author":"Conley","year":"2020","journal-title":"J Bone Miner Res"},{"key":"2023101816055417300_dgad295-B23","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgad161","article-title":"Response to letter to the editor from Riahi and Gruntmanis: \u2018inpatient zoledronic acid and integrated orthopedic and fracture liaison services improve osteoporosis treatment rates","volume":"108","author":"Fan","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"19","key":"2023101816055417300_dgad295-B24","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.2106\/JBJS.K.01434","article-title":"Early initiation of bisphosphonate does not affect healing and outcomes of volar plate fixation of osteoporotic distal radial fractures","volume":"94","author":"Gong","year":"2012","journal-title":"J Bone Joint Surg Am"},{"key":"2023101816055417300_dgad295-B25","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.688269","article-title":"The effect of bisphosphonates on fracture healing time and changes in bone mass density: a meta-analysis","volume":"12","author":"Gao","year":"2021","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad295\/50516643\/dgad295.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/11\/e1282\/52218008\/dgad295.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/11\/e1282\/52218008\/dgad295.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T16:09:09Z","timestamp":1697645349000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/11\/e1282\/7179535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":25,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,5,25]]},"published-print":{"date-parts":[[2023,10,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad295","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,5,25]]}}}